Uveitis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Uveitis – Pipeline Review, H2 2017’, provides an overview of the Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Uveitis

The report reviews pipeline therapeutics for Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Uveitis therapeutics and enlists all their major and minor projects

The report assesses Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Uveitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Uveitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

AbbVie Inc

Aciont Inc

Alcon Laboratories Inc

Aldeyra Therapeutics Inc

Apitope International NV

Bionomics Ltd

Bristol-Myers Squibb Co

Can-Fite BioPharma Ltd

Clearside BioMedical Inc

Coherus BioSciences Inc

Elasmogen Ltd

Endocyte Inc

Enzo Biochem Inc

EyeGate Pharmaceuticals Inc

Eyevensys SAS

F. Hoffmann-La Roche Ltd

Galapagos NV

HanAll Biopharma Co Ltd

Icon Bioscience Inc

Idera Pharmaceuticals Inc

Johnson & Johnson

KPI Therapeutics Inc

Midatech Pharma Plc

Mitotech SA

Nemus Bioscience Inc

Novartis AG

Oculis ehf

OncoNOx ApS

Ophthotech Corp

Orchid Pharma Ltd

Palatin Technologies Inc

Panoptes Pharma GesmbH

pSivida Corp

Re-Pharm Ltd

Santen Pharmaceutical Co Ltd

SynDevRx Inc

TxCell SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Uveitis - Overview 8

Uveitis - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Uveitis - Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Uveitis - Companies Involved in Therapeutics Development 30

2-BBB Medicines BV 30

AbbVie Inc 30

Aciont Inc 31

Alcon Laboratories Inc 31

Aldeyra Therapeutics Inc 31

Apitope International NV 32

Bionomics Ltd 32

Bristol-Myers Squibb Co 33

Can-Fite BioPharma Ltd 33

Clearside BioMedical Inc 34

Coherus BioSciences Inc 34

Elasmogen Ltd 35

Endocyte Inc 35

Enzo Biochem Inc 35

EyeGate Pharmaceuticals Inc 36

Eyevensys SAS 36

F. Hoffmann-La Roche Ltd 37

Galapagos NV 37

HanAll Biopharma Co Ltd 38

Icon Bioscience Inc 38

Idera Pharmaceuticals Inc 38

Johnson & Johnson 39

KPI Therapeutics Inc 39

Midatech Pharma Plc 40

Mitotech SA 40

Nemus Bioscience Inc 41

Novartis AG 41

Oculis ehf 42

OncoNOx ApS 42

Ophthotech Corp 42

Orchid Pharma Ltd 43

Palatin Technologies Inc 43

Panoptes Pharma GesmbH 44

pSivida Corp 44

Re-Pharm Ltd 45

Santen Pharmaceutical Co Ltd 45

SynDevRx Inc 45

TxCell SA 46

Uveitis - Drug Profiles 47

2B-3201 - Drug Profile 47

abatacept - Drug Profile 49

adalimumab - Drug Profile 58

adalimumab biosimilar - Drug Profile 67

adalimumab biosimilar - Drug Profile 70

adalimumab biosimilar - Drug Profile 73

adalimumab biosimilar - Drug Profile 74

ADX-102 - Drug Profile 75

Antisense Oligonucleotide to Inhibit NLRP3 for Inflammatory Disorders - Drug Profile 81

Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile 82

ANV-103 - Drug Profile 83

ATXUV-1 - Drug Profile 84

avacincaptad pegol sodium - Drug Profile 85

B27-PD - Drug Profile 88

BNC-164 - Drug Profile 89

Col-Treg - Drug Profile 90

CVX-001 - Drug Profile 92

cyclosporine SR - Drug Profile 93

dalazatide - Drug Profile 94

dexamethasone acetate - Drug Profile 99

dexamethasone acetate - Drug Profile 105

dexamethasone sodium phosphate - Drug Profile 107

Drug for Chronic Uveitis - Drug Profile 109

Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 110

EBI-031 - Drug Profile 111

EC-1669 - Drug Profile 112

ELN-21 - Drug Profile 113

ELN-22 - Drug Profile 114

EYS-606 - Drug Profile 115

filgotinib - Drug Profile 116

fluocinolone acetonide SA - Drug Profile 129

fluocinolone acetonide SR - Drug Profile 130

FR-104 - Drug Profile 139

Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile 142

HL-036 - Drug Profile 143

HO-10 - Drug Profile 144

IVMED-10 - Drug Profile 145

IVMED-20 - Drug Profile 146

KPI-190 - Drug Profile 147

latanoprost SR - Drug Profile 148

LME-636 - Drug Profile 149

lodamin - Drug Profile 150

methotrexate - Drug Profile 151

NB-2222 - Drug Profile 152

OX-1001 - Drug Profile 153

piclidenoson - Drug Profile 154

PL-8177 - Drug Profile 164

plastoquinone decyl triphenylphosphonium bromide - Drug Profile 165

PP-001 - Drug Profile 167

PPL-003 - Drug Profile 169

RP-0217 - Drug Profile 171

sirolimus - Drug Profile 172

Small Molecule to Inhibit PDE4B and TNF Alpha for Asthma, COPD and Uveitis - Drug Profile 176

Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile 177

Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile 178

tesidolumab - Drug Profile 179

triamcinolone acetonide - Drug Profile 181

Uveitis - Dormant Projects 188

Uveitis - Discontinued Products 191

Uveitis - Product Development Milestones 192

Featured News & Press Releases 192

Appendix 203

Methodology 203

Coverage 203

Secondary Research 203

Primary Research 203

Expert Panel Validation 203

Contact Us 203

Disclaimer 204

List of Tables

List of Tables

Number of Products under Development for Uveitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Uveitis – Pipeline by 2-BBB Medicines BV, H2 2017

Uveitis – Pipeline by AbbVie Inc, H2 2017

Uveitis – Pipeline by Aciont Inc, H2 2017

Uveitis – Pipeline by Alcon Laboratories Inc, H2 2017

Uveitis – Pipeline by Aldeyra Therapeutics Inc, H2 2017

Uveitis – Pipeline by Apitope International NV, H2 2017

Uveitis – Pipeline by Bionomics Ltd, H2 2017

Uveitis – Pipeline by Bristol-Myers Squibb Co, H2 2017

Uveitis – Pipeline by Can-Fite BioPharma Ltd, H2 2017

Uveitis – Pipeline by Clearside BioMedical Inc, H2 2017

Uveitis – Pipeline by Coherus BioSciences Inc, H2 2017

Uveitis – Pipeline by Elasmogen Ltd, H2 2017

Uveitis – Pipeline by Endocyte Inc, H2 2017

Uveitis – Pipeline by Enzo Biochem Inc, H2 2017

Uveitis – Pipeline by EyeGate Pharmaceuticals Inc, H2 2017

Uveitis – Pipeline by Eyevensys SAS, H2 2017

Uveitis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Uveitis – Pipeline by Galapagos NV, H2 2017

Uveitis – Pipeline by HanAll Biopharma Co Ltd, H2 2017

Uveitis – Pipeline by Icon Bioscience Inc, H2 2017

Uveitis – Pipeline by Idera Pharmaceuticals Inc, H2 2017

Uveitis – Pipeline by Johnson & Johnson, H2 2017

Uveitis – Pipeline by KPI Therapeutics Inc, H2 2017

Uveitis – Pipeline by Midatech Pharma Plc, H2 2017

Uveitis – Pipeline by Mitotech SA, H2 2017

Uveitis – Pipeline by Nemus Bioscience Inc, H2 2017

Uveitis – Pipeline by Novartis AG, H2 2017

Uveitis – Pipeline by Oculis ehf, H2 2017

Uveitis – Pipeline by OncoNOx ApS, H2 2017

Uveitis – Pipeline by Ophthotech Corp, H2 2017

Uveitis – Pipeline by Orchid Pharma Ltd, H2 2017

Uveitis – Pipeline by Palatin Technologies Inc, H2 2017

Uveitis – Pipeline by Panoptes Pharma GesmbH, H2 2017

Uveitis – Pipeline by pSivida Corp, H2 2017

Uveitis – Pipeline by Re-Pharm Ltd, H2 2017

Uveitis – Pipeline by Santen Pharmaceutical Co Ltd, H2 2017

Uveitis – Pipeline by SynDevRx Inc, H2 2017

Uveitis – Pipeline by TxCell SA, H2 2017

Uveitis – Dormant Projects, H2 2017

Uveitis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Uveitis – Dormant Projects, H2 2017 (Contd..2), H2 2017

Uveitis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Uveitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports